EMP3 sustains oncogenic EGFR/CDK2 signaling by restricting receptor degradation in glioblastoma.
Martija AA, Krauß A, Bächle N, Doth L, Christians A, Krunic D, Schneider M, Helm D, Will R, Hartmann C, Herold-Mende C, von Deimling A, Pusch S.
Martija AA, et al. Among authors: krunic d.
Acta Neuropathol Commun. 2023 Nov 7;11(1):177. doi: 10.1186/s40478-023-01673-z.
Acta Neuropathol Commun. 2023.
PMID: 37936247
Free PMC article.